Five-fraction breast SBRT maintains favorable cosmesis in 74% at three years

In a 23-patient phase I study, five-fraction partial-breast SBRT produced no in-breast recurrences, while favorable cosmesis declined to 73.7% at three years.

KEY POINTS

  • RAD1802 was a prospective single-center phase I pilot study from the University of Alabama at Birmingham, enrolling 23 women with early-stage breast cancer between August 2019 and April 2021. Patients met the 2017 ASTRO accelerated partial-breast irradiation (APBI) suitability criteria, including age ≥50 years, small tumors, node-negative disease, and appropriate surgical margins. One woman underwent bilateral treatment, resulting in 24 treated breast targets, and 20 patients remained on study at 36 months.
  • SBRT-based APBI delivered 30 Gy in five once-daily fractions using a standard linear accelerator with a three-dimensional BioZorb tissue marker placed during lumpectomy. The CTV was generated with a 10-mm lumpectomy-cavity expansion, followed by a 3-mm PTV margin, with exclusion of relevant anatomical structures. Mean PTV volume was 80.8 cm³, and the protocol generally required PTV ≤124 cm³. Treatments were delivered prone or supine using IMRT or VMAT, with triggered intrafraction imaging and automatic beam interruption for marker displacement exceeding 3 mm.
  • The predefined feasibility and acute safety objectives were met. All 23 patients completed treatment and the six-month assessment, with no irreversible grade ≥3 acute toxicity attributable to SBRT, satisfying the protocol's primary endpoint. Most recorded acute adverse events were grade 1, including dermatitis, breast tenderness, pruritus, pigment changes, and edema. Across extended follow-up, three grade 3 late adverse events were recorded, but none was considered related to SBRT.
  • Patient-reported cosmetic outcomes declined from baseline but remained favorable in most patients. Excellent or good cosmesis was reported by 86.4% at baseline, decreasing to 73.7% (14/19) at 36 months. Nurse-rated excellent or good cosmesis was 78.9% (15/19) at the same time point. Poor cosmesis was reported in 2/19 patients (10.5%) by both patient and nurse assessment at three years, demonstrating that a minority experienced substantial cosmetic deterioration despite favorable overall ratings.
  • No ipsilateral breast tumor recurrence or distant metastasis was reported during follow-up, although two ipsilateral axillary nodal recurrences occurred at six and 18 months. Both affected patients subsequently withdrew from the study. With only 23 participants and limited oncological events, the absence of in-breast recurrence cannot establish disease-control equivalence to larger prospective APBI or whole-breast irradiation series.
  • Fat necrosis and breast tissue changes remained relevant to cosmetic outcomes. Fat necrosis was documented in three of six patients classified as having fair or poor cosmesis, compared with two of 17 patients classified as excellent or good in the reported analysis. Functional status remained favorable: no patient developed Zubrod performance status ≥2, and 90% of evaluable patients retained performance status 0 at three years. However, the Zubrod scale provides limited information about breast-specific function or patient-reported quality of life.
  • The imaging and immobilization approach has important limitations for broader implementation. The BioZorb device enabled tight treatment margins and intrafraction tracking, but persistent implant material may have contributed to cosmetic concerns, and the device was subsequently withdrawn from the market. Treatment positioning also varied between patients. Without a control arm, external validation, or longer follow-up in a larger population, this study supports feasibility rather than demonstrating superiority over established APBI approaches.

CLINICAL TAKEAWAY

Five-fraction SBRT-based partial-breast irradiation achieved protocol-defined safety and feasibility endpoints, with most evaluable patients maintaining excellent or good cosmetic outcomes at three years. However, favorable cosmesis declined from baseline, and two regional nodal failures occurred despite the absence of in-breast recurrence. The very small single-arm cohort and subsequent withdrawal of the localization device limit direct translation of this specific technique into routine practice.

SOURCE

Advances in Radiation Oncology

Browse more research Suggest a correction